- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
F/m Emerald Life Sciences Innovation ETF(LFSC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LFSC
11/20/2026: LFSC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
The F/m Emerald Life Sciences Innovation ETF (LFSC) provides actively managed exposure to innovative U.S. life sciences companies spanning biotechnology, pharmaceuticals, and medical devices. Its main strengths lie in experienced active management and specialized stock selection designed to capture high-growth clinical breakthroughs. It serves primarily as a satellite growth allocation for capturing sector alpha rather than a core portfolio holding. Key risks include high volatility, clinical trial vulnerability, and portfolio concentration. It best suits aggressive growth investors who should monitor regulatory milestones and sector liquidity.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The fund targets cutting-edge life sciences companies positioned for rapid capital appreciation. |
| Momentum investor | Strong fit while signal remains positive | Strong recent price momentum in biotech innovations appeals to trend-following participants. |
| Value investor | Weak fit | Many underlying holdings prioritize clinical pipeline development over immediate earnings or free cash flow. |
| Dividend/Income investor | Weak fit | The fund focuses purely on capital growth and does not distribute meaningful dividend yields. |
| Low-risk investor | Weak fit | High exposure to clinical-stage biotech creates substantial volatility unsuited for conservative profiles. |
Investor Profile
Ideal Investor Profile
Growth-oriented investors seeking targeted exposure to pioneering life sciences companies through active management.
Suitability
Best suited for long-term investors willing to tolerate high sector volatility in exchange for potential alpha.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Clinical trial results and regulatory decisions can trigger sharp price swings in underlying biotech stocks. |
| Market risk | Medium / high | Broader risk-off sentiment in equities can disproportionately impact speculative healthcare innovators. |
| Concentration | High | A significant percentage of assets is clustered within a relatively small number of top holdings. |
| Tracking/expense | Medium | Active management entails a higher expense ratio than passive index alternatives. |
| Liquidity | Medium / high | Lower average daily volume can lead to wider execution spreads during turbulent market sessions. |
| Business/sector quality | Medium | Many target companies are pre-revenue entities reliant on successful drug commercialization. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
LFSC exhibits high historical volatility characteristic of clinical-stage biotech and specialized healthcare equities.
Market Risk
Subject to regulatory approvals, clinical trial outcomes, and shifting sentiment toward high-growth, non-earnings-yielding equities.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Sector | Healthcare and Life Sciences Equities | Provides focused exposure to innovative biotechnology, pharmaceutical, and medical device companies. | |
| Single stock | Top Life Sciences Holdings (e.g., Cogent Biosciences, LivaNova, Mirum Pharmaceuticals) | Represents high-conviction active bets on clinical-stage or commercial-stage medical breakthroughs. |
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit 68.93% | Avg. Invested days 91 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

